Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688013's EV-to-EBITDA is ranked worse than 78.25% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 13.63
vs SHSE:688013: 29.06
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Touchstone International Medical Science Co (SHSE:688013) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Touchstone International Medical Science Co's PE Ratio (TTM) for today is calculated as:
Touchstone International Medical Science Co's share price for today is ¥22.32.
Touchstone International Medical Science Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.630.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Touchstone International Medical Science Co EV-to-EBITDA Chart
Touchstone International Medical Science Co Annual Data
SHSE:688013 vs ISRG, BDX, RMD: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Touchstone International Medical Science Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Touchstone International Medical Science Co EV-to-EBITDA vs Medical Devices & Instruments Industry
Touchstone International Medical Science Co's current Enterprise Value is ¥1,690.3 Mil.
Touchstone International Medical Science Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥58.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Touchstone International Medical Science Co (SHSE:688013) has a EV-to-EBITDA of 29.06 as of Sep. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Touchstone International Medical Science Co. This is 14% below median its historical median of 33.84. Over the past decade, Touchstone International Medical Science Co's EV-to-EBITDA has ranged from 13.84 to 68.54. According to the industry distribution chart, Touchstone International Medical Science Co ranks #403 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 78.3%.
Is Touchstone International Medical Science Co's EV-to-EBITDA too high?
Touchstone International Medical Science Co's current EV-to-EBITDA of 29.06 is 14% below median its 10-year median of 33.84. Over the past 10 years, this metric has ranged from a low of 13.84 to a high of 68.54. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.63. Touchstone International Medical Science Co's value of 29.06 is 113.2% above this industry median. Based on the distribution chart, Touchstone International Medical Science Co ranks #403 out of 515 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Touchstone International Medical Science Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Touchstone International Medical Science Co's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Touchstone International Medical Science Co ranks #403 out of 515 companies for EV-to-EBITDA. This places Touchstone International Medical Science Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.63. Touchstone International Medical Science Co's value of 29.06 is 113.2% above this benchmark. Historically, Touchstone International Medical Science Co's own EV-to-EBITDA has ranged from 13.84 to 68.54 over the past decade. While the company's 10-year median is 33.84 vs. the industry median of 13.63, Touchstone International Medical Science Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.63, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Touchstone International Medical Science Co's current EV-to-EBITDA of 29.06 is 113.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Touchstone International Medical Science Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Touchstone International Medical Science Co's current EV-to-EBITDA is 29.06, which is 14% below median its own 10-year median of 33.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Touchstone International Medical Science Co stock overvalued right now?
Based on GuruFocus' analysis, Touchstone International Medical Science Co (SHSE:688013) is currently considered Fairly Valued. The stock's GF Value™ is ¥24.35, compared to a current price of ¥22.32 — trading 8.3% below its estimated fair value. The current EV-to-EBITDA is 29.06, which is 14% below median its 10-year median of 33.84 and 113.2% above the Medical Devices & Instruments industry median of 13.63. Touchstone International Medical Science Co's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Touchstone International Medical Science Co (SHSE:688013), the current EV-to-EBITDA is 29.06 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Touchstone International Medical Science Co (SHSE:688013) Overvalued in 2026?
Based on GuruFocus' analysis, Touchstone International Medical Science Co stock appears to be undervalued.
The current stock price of ¥22.32 is trading 8.3% below its estimated GF Value™ of ¥24.35.
GuruFocus considers Touchstone International Medical Science Co to be Fairly Valued.
Key valuation signals for SHSE:688013:
EV-to-EBITDA: 29.06 (14% below median its 10-year median of 33.84)
GF Value™: ¥24.35 vs. price of ¥22.32 (8.3% below fair value)
Industry Position: 113.2% above the Medical Devices & Instruments median (#403 of 515)
No single metric tells the full story. See the SHSE:688013 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Touchstone International Medical Science Co Ltd is specialized in the development of surgical staplers that enhance clinical performance, minimise risk and improve patient outcomes. The company's products include Auto Purse String Clamp for Single Use (APS); Intraluminal Stapler for Single Use (CSC&ECSC); Endoscopic Linear Cutter and Single Use Loading Unit (ELC&ELCC); Intraluminal Stapler for Single Use (KOL); Linear Cutter and Reloads (LC&LCC); Linear Stapler and Reloads (LS&LSC); PPH Stapler and Purse Sets for Single Use (PPH); Tissue - Selecting Therapy Stapler (TST33); Tissue - Selecting Therapy Stapler (TST36); and Tissue - Selecting Therapy Stapler (Proctology Examination Kit).
79GF Score
Get the complete analysis for SHSE:688013
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688013 has been successfully added to your 
